Entrada Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Entrada Therapeutics has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 130.6% per year. Entrada Therapeutics's return on equity is 24.3%, and it has net margins of 43.6%.
Información clave
19.0%
Tasa de crecimiento de los beneficios
66.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 130.6% |
| Rentabilidad financiera | 24.3% |
| Margen neto | 43.6% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Desglose de ingresos y gastos
Cómo gana y gasta dinero Entrada Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 239 | 104 | 35 | 0 |
| 31 Mar 24 | 163 | 23 | 34 | 0 |
| 31 Dec 23 | 129 | -7 | 32 | 0 |
| 30 Sep 23 | 87 | -22 | 34 | 67 |
| 30 Jun 23 | 43 | -82 | 33 | 0 |
| 31 Mar 23 | 25 | -80 | 32 | 0 |
| 31 Dec 22 | 0 | -95 | 31 | 0 |
| 30 Sep 22 | 0 | -88 | 27 | 12 |
| 30 Jun 22 | 0 | -78 | 24 | 23 |
| 31 Mar 22 | 0 | -64 | 19 | 30 |
| 31 Dec 21 | 0 | -51 | 15 | 36 |
| 30 Sep 21 | 0 | -41 | 11 | 30 |
| 30 Jun 21 | 0 | -34 | 9 | 25 |
| 31 Mar 21 | 0 | -29 | 7 | 23 |
| 31 Dec 20 | 0 | -27 | 6 | 21 |
Ingresos de calidad: TRDA has high quality earnings.
Margen de beneficios creciente: TRDA became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: TRDA has become profitable over the past 5 years, growing earnings by 19% per year.
Acelerando crecimiento: TRDA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: TRDA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: TRDA's Return on Equity (24.3%) is considered high.